We can safely conclude that the single‐chain antibody recombinant immune molecules fused with apoptotic proteins constructed in this study effectively targeted the breast cancer surface receptor, HER‐2, and induced apoptosis both in vivo and in vitro. Here, ERBB2 is linked to breast carcinoma.